Prendergast Heather M, Dudley Samuel, Brown Michael, Daviglus Martha, Kane John, Bradshaw Bunney E, Marcucci Jared, Sanyaolu Rasheed
Department of Emergency Medicine, University of Illlinois Hospital & Health Sciences System, 808 S. Wood Rm 471-H, Chicago, IL, 60612, USA,
High Blood Press Cardiovasc Prev. 2014 Dec;21(4):269-74. doi: 10.1007/s40292-014-0064-1. Epub 2014 Jun 28.
There have been no studies examining the association between antihypertensive medications and progression of diastolic dysfunction. The purpose of this study is to determine whether there is an association between class of antihypertensive medication and diastolic dysfunction progression in an African American population.
A retrospective cohort study of African American patients with at least two echocardiograms demonstrating diastolic dysfunction drawn from an echocardiogram database at an academic medical center. The main outcome measures were change in diastolic function grade as a function of time and association with hypertension medication classification.
There were 96 African American patients in the database with 2 or more echocardiograms demonstrating diastolic dysfunction; representing 302 echocardiograms. The mean time between echocardiograms was 2.6 years. The mean age was 64.2 (±10.1) years, 78 % were women, and mean BMI 31.2 (±7.4) kg/m(2). The majority of subjects had Grade I diastolic dysfunction at their initial examination [N = 87 (90.6 %)]. Approximately 22.9 % (n = 22) of the study cohort demonstrated diastolic dysfunction progression. In multivariate analysis use of calcium channel blockers (CCB) was protective against diastolic dysfunction progression (OR for CCB users vs. non-users 0.28, 95 % confidence interval, 0.09-0.90, p < 0.05).
These findings suggest that use of calcium channel blockers may have a protective effect against progression of diastolic dysfunction among African American patients. Further studies are required to confirm these findings and identify specific factors that can mediate disease progression among African American individuals with hypertension, who face substantial risk of complications such as diastolic heart failure.
尚无研究探讨抗高血压药物与舒张功能障碍进展之间的关联。本研究旨在确定非裔美国人中抗高血压药物类别与舒张功能障碍进展之间是否存在关联。
一项回顾性队列研究,纳入来自某学术医学中心超声心动图数据库的至少有两次超声心动图显示舒张功能障碍的非裔美国患者。主要结局指标为舒张功能分级随时间的变化以及与高血压药物分类的关联。
数据库中有96名非裔美国患者有2次或更多次超声心动图显示舒张功能障碍;共302次超声心动图。超声心动图之间的平均时间间隔为2.6年。平均年龄为64.2(±10.1)岁,78%为女性,平均体重指数为31.2(±7.4)kg/m²。大多数受试者在初次检查时为I级舒张功能障碍[N = 87(90.6%)]。约22.9%(n = 22)的研究队列显示舒张功能障碍进展。在多变量分析中,使用钙通道阻滞剂(CCB)可预防舒张功能障碍进展(CCB使用者与非使用者的比值比为0.28,95%置信区间为0.09 - 0.90,p < 0.05)。
这些发现表明,使用钙通道阻滞剂可能对非裔美国患者舒张功能障碍的进展具有保护作用。需要进一步研究来证实这些发现,并确定可介导高血压非裔美国人疾病进展的具体因素,这些患者面临舒张性心力衰竭等并发症的重大风险。